Title: Childhood Cancer STAR Reauthorization Act of 2022
Policy area: Health

Summary:
Childhood Cancer Survivorship, Treatment, Access, and Research Reauthorization Act of 2022 or the Childhood Cancer STAR Reauthorization Act
This bill reauthorizes through FY2028 and modifies pediatric cancer research and related programs, including to expand collection of and access to relevant biospecimens and to support the transition of pediatric cancer survivors to primary care.

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7630 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 7630

To maximize discovery, and accelerate development and availability, of 
     promising childhood cancer treatments, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             April 28, 2022

Mr. McCaul (for himself, Ms. Speier, Mr. Butterfield, and Mr. Kelly of 
Pennsylvania) introduced the following bill; which was referred to the 
                    Committee on Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
To maximize discovery, and accelerate development and availability, of 
     promising childhood cancer treatments, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Childhood Cancer Survivorship, 
Treatment, Access, and Research Reauthorization Act of 2022'' or the 
``Childhood Cancer STAR Reauthorization Act of 2022''.

SEC. 2. REAUTHORIZING AND IMPROVING THE CHILDHOOD STAR ACT.

    (a) Children's Cancer Biorepositories.--Section 417E of the Public 
Health Service Act (42 U.S.C. 285a-11) is amended--
            (1) in subsection (a)--
                    (A) in paragraph (2)(A), by inserting before the 
                period at the end of the second sentence the following: 
                ``, and providing sample collection incentives for both 
                solid tumor cancer and paired tissues for all pediatric 
                cancers'';
                    (B) in paragraph (9), by striking ``Childhood 
                Cancer Survivorship, Treatment, Access, and Research 
                Act of 2018'' and inserting ``Childhood Cancer 
                Survivorship, Treatment, Access, and Research 
                Reauthorization Act of 2022'';
                    (C) by redesignating paragraph (10) as paragraph 
                (11); and
                    (D) by inserting after paragraph (9) the following:
            ``(10) Report on researcher access to children's cancer 
        biorepository samples.--The Director of NIH shall, not later 
        than 2 years after the date of enactment of the Childhood 
        Cancer Survivorship, Treatment, Access, and Research 
        Reauthorization Act of 2022, submit to Congress a report on 
        policy changes that would facilitate streamlining the approval 
        process for researcher access to children's cancer 
        biorepository samples, with a special focus on lowering the 
        regulatory burden before samples can be sent to 
        investigators.''; and
            (2) in subsection (d), by striking ``2019 through 2023'' 
        and inserting ``2024 through 2028''.
    (b) Cancer Survivorship Programs.--Section 201 of the Childhood 
Cancer Survivorship, Treatment, Access, and Research Act of 2018 
(Public Law 115-180) is amended--
            (1) in subsection (a)--
                    (A) in paragraph (1), by striking ``may make 
                awards'' and inserting ``shall make awards''; and
                    (B) by adding at the end the following:
            ``(4) Consideration.--In developing, studying, and 
        evaluating model systems pursuant to this subsection, 
        recipients of awards under this subsection shall give 
        particular consideration to the report issued by the Agency for 
        Healthcare Research and Quality in February 2022, titled 
        `Models of Care That Include Primary Care for Adult Survivors 
        of Childhood Cancer: A Realist Review'.''; and
            (2) in subsection (b), in paragraphs (1) and (2), by 
        striking ``date of enactment of this Act'' each place it 
        appears and inserting ``date of enactment of the Childhood 
        Cancer Survivorship, Treatment, Access, and Research 
        Reauthorization Act of 2022''.
    (c) Survivorship Electronic Health Records.--The Secretary of 
Health and Human Services shall coordinate with the Office of the 
National Coordinator for Health Information to prepare a report on the 
role that tailored survivorship electronic health records can play in 
life-long health care for childhood cancer survivors, with a special 
focus on survivors who face unique lifelong health needs and late 
effects as they transition to primary care. Such report shall be 
submitted to Congress not later than 2 years after the date of 
enactment of this Act.
    (d) Sense of Congress Regarding the Creation of a Childhood Cancer 
Medical Code.--It is the sense of Congress that the National Center for 
Health Statistics at the Centers for Disease Control and Prevention and 
the Centers for Medicare & Medicaid Services should consider adding a 
new Childhood Cancer Code to the International Classification of 
Diseases (ICD) system for the purpose of facilitating access to 
existing insurance coverage of childhood cancer patients and survivors, 
as appropriate.
                                 <all>